Last reviewed · How we verify

EpicentRx, Inc. — Portfolio Competitive Intelligence Brief

EpicentRx, Inc. pipeline: 0 marketed, 0 filed, 2 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 2 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Cisplatin/carboplatin plus etoposide Cisplatin/carboplatin plus etoposide phase 3 Combination chemotherapy DNA (platinum agents); Topoisomerase II (etoposide) Oncology
RRx-001 + eLOOP Device RRx-001 + eLOOP Device phase 3 Immunotherapeutic small molecule Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Children's Cancer Group, China · 1 shared drug class
  2. Sumitomo Pharma (Suzhou) Co., Ltd. · 1 shared drug class
  3. Taiho Pharmaceutical Co., Ltd. · 1 shared drug class
  4. The First Affiliated Hospital with Nanjing Medical University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for EpicentRx, Inc.:

Cite this brief

Drug Landscape (2026). EpicentRx, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/epicentrx-inc. Accessed 2026-05-14.

Related